Novartis AG (0QLR.IL)
| Previous Close | 98.87 |
| Open | 0.00 |
| Bid | 96.81 x N/A |
| Ask | 0.00 x N/A |
| Day's Range | 0.00 - 0.00 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 501,739 |
| Market Cap | 227.647B |
| Beta (5Y Monthly) | 0.49 |
| PE Ratio (TTM) | 30.93 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.20 (3.78%) |
| Ex-Dividend Date | Mar 09, 2023 |
| 1y Target Est | N/A |
- GlobeNewswire
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager to receive upfront consideration of $15 million and is eligible to receive up to $305 million in potential associated milestone payments and royaltiesLEXINGTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Novartis AG (NYSE: NVS) has agreed to license a novel capsid generated from Voyager’s TRACER™ capsid discovery platform for use in a gene therapy program
- Business Wire
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
RALEIGH, N.C., August 28, 2024--Lindy Biosciences, a pioneering biotechnology company specializing in innovative drug formulation and delivery technologies, today announced a multi-target exclusive global licensing agreement and strategic collaboration with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS), an innovative medicines company.
- GlobeNewswire
Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
Phase III V-MONO study met its primary endpoints, demonstrating superiority of Leqvio (inclisiran) monotherapy vs both placebo and ezetimibe in LDL-C reduction1 Results add to growing body of evidence for Leqvio across the ASCVD continuum Data will be shared with regulatory agencies and presented at an upcoming medical meeting V-MONO is part of the 60,000-patient VictORION clinical trial program assessing Leqvio for primary and secondary ASCVD prevention Basel, August 28, 2024 – Novartis announc
